Search research articles
Contact Us
Filters
Showing results (541-550 of 616) with videos related to
Page
of 62
Sort By:
Journal of Microbiology and Biotechnology
|
July 28, 2011
Homologous expression and quantitative analysis of T3SS-dependent secretion of TAP-tagged XoAvrBs2 in Xanthomonas oryzae pv. oryzae induced by rice leaf extract
S H Kim, S E Lee, M-K Hong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 3, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
G Goss, C-M Tsai, F A Shepherd, et al.
Biorxiv : the Preprint Server for Biology
|
May 20, 2024
MEK signaling represents a viable therapeutic vulnerability of KRAS-driven somatic brain arteriovenous malformations
Carlos Flores Suarez, Omar Ashraf Harb, Ariadna Robledo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H Yoshioka, K Azuma, N Yamamoto, et al.
Alimentary Pharmacology & Therapeutics
|
October 30, 2015
Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study
J Ahn, H M Lee, J K Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
S-H Lee, J-K Lee, M-J Ahn, et al.
Clinical, Cosmetic and Investigational Dermatology
|
January 11, 2020
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Shaundra Eichstadt, Jean Y Tang, Daniel C Solis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2020
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
J H Shim, H S Kim, H Cha, et al.
ESMO Open
|
February 14, 2022
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
S Park, J-M Sun, Y-L Choi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G R Oxnard, J C-H Yang, H Yu, et al.
Page
of 62
Search research articles
Search
Showing results (541-550 of 616) with videos related to
Sort By:
Page
of 62
Journal of Microbiology and Biotechnology
|
July 28, 2011
Homologous expression and quantitative analysis of T3SS-dependent secretion of TAP-tagged XoAvrBs2 in Xanthomonas oryzae pv. oryzae induced by rice leaf extract
S H Kim, S E Lee, M-K Hong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 3, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
G Goss, C-M Tsai, F A Shepherd, et al.
Biorxiv : the Preprint Server for Biology
|
May 20, 2024
MEK signaling represents a viable therapeutic vulnerability of KRAS-driven somatic brain arteriovenous malformations
Carlos Flores Suarez, Omar Ashraf Harb, Ariadna Robledo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H Yoshioka, K Azuma, N Yamamoto, et al.
Alimentary Pharmacology & Therapeutics
|
October 30, 2015
Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study
J Ahn, H M Lee, J K Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
S-H Lee, J-K Lee, M-J Ahn, et al.
Clinical, Cosmetic and Investigational Dermatology
|
January 11, 2020
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Shaundra Eichstadt, Jean Y Tang, Daniel C Solis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2020
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
J H Shim, H S Kim, H Cha, et al.
ESMO Open
|
February 14, 2022
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
S Park, J-M Sun, Y-L Choi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G R Oxnard, J C-H Yang, H Yu, et al.
Page
of 62